Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma

NCT03481231 is registered in ClinicalTrials.gov with Centre Georges Francois Leclerc as lead sponsor.

NCT NCT03481231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03481231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma
Lead sponsor
Centre Georges Francois Leclerc
Phase
Observational
Overall status
Completed
Start date
September 13, 2020
Completion date
September 14, 2024
Enrollment
160 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma